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The sensitivities of three methods of detection of Mycoplasma pneumoniae by a 16S rDNA PCR were
compared by using a serial dilution ofM. pneumoniae. These methods consisted of a PCR performed directly
on cells after a proteinase K pretreatment (direct PCR), a PCR after purification of nucleic acids (DNA-PCR),
and a PCR with rRNA sequences as the target after reverse transcription. The direct PCR and the reverse
transcription PCR had a sensitivity of 1.5 CFU (=250 genomes). By purification, a 10-fold loss of target DNA
occurred, as shown by a 10-fold decrease in sensitivity (15 CFU) of the DNA-PCR. The presence of an excess
of human background DNA did not influence the sensitivity of either PCR. The direct PCR was evaluated on
samples from patients with respiratory complaints. Direct PCR amplification was possible in 94.9%o of the
samples, which were tested by amplification of a 326-bp fament of the j-globin gene, which was performed
to test for the suitability of amplification. Nucleic acid purification was performed on the P-globin-negative
samples, after which only 2% remained negative. A positive correlation between the direct M. pneumoniae
PCR and serology, as tested by the microparticle agglutination assay (MAG assay), was found in 88.1% of the
cases. A positive MAG assay result was found for samples from 10 (17%) of the patients; samples from 6
(10.2%) of these patients were also positive by PCR. Samples from three patients were found to be positive by
the M. pneumorniae PCR and negative by the MAG assay. Persistence ofM. pneumoniae, as detected by PCR,
was observed in three patients. These results indicate that the direct PCR with 16S rDNA could prove to be
useful in the detection of M. pneumoniae in respiratory tract samples, although more studies are needed to
evaluate the correlation between clinical symptoms and a positive test result.
Mycoplasma pneumoniae is a common cause of commu-
nity-acquired respiratory tract infections, especially in chil-
dren and young adults. Approximately 10% of the cases of
community-acquired pneumonia that occur in endemic peri-
ods and up to 50% of the cases that occur in epidemic
periods are caused byM. pneumoniae (5). Rapid diagnosis of
an M. pneumoniae infection is important, since M. pneumo-
niae is not sensitive to 3-lactam antibiotics, which are most
often used empirically in the treatment of lower respiratory
infections.
In routine laboratory practice, serology is used for the
diagnosis of M. pneumoniae infections, since culture is
relatively insensitive and 3 weeks or more may be required
to obtain a result. In patients with primary infections,
immunoglobulin M (IgM) can be detected from 7 days after
the onset of symptoms and reaches a peak within 2 to 3
weeks. In patients with reinfections, IgM is mostly absent.
Therefore, paired sera are used to confirm reinfection by M.
pneumoniae, which is demonstrated by a fourfold rise in titer
in IgG antibodies (13, 17). This can be observed only when
the first serum sample is taken within 10 days after the onset
of disease (5). Sillis (17) showed that in the absence of IgM
antibodies in patients with reinfections, IgA measurement in
a single serum sample can be used for diagnosis. Thus, both
in patients with primary infections and in patients with
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reinfections, serological diagnosis is not obtained before 1
week after the onset of symptoms.
Therefore, rapid direct tests such as antigen detection,
hybridization with DNA probes, and recently, PCR have
been developed. PCR seems to be the most promising direct
technique because of its high sensitivity and specificity (4).
Different PCRs for the detection of M. pneumoniae have
been described. The targets are the gene coding for the P1
adhesion protein, the 16S rRNA gene, and a DNA sequence
specific for M. pneumoniae selected from a genomic library
(1, 11, 20). In different studies, the use of 16S rDNA
sequences has been described for the detection of several
microorganisms such as mycobacteria, Helicobacterpylori,
and mycoplasmas (2, 10, 20). The advantage of using 16S
rRNA sequences is the high degree of conservation of the
target and the presence of a high copy number of rRNA
molecules in the cell, which are available as templates for the
PCR after reverse transcription (RT) to DNA (RT-PCR).
However, a disadvantage of an RT-PCR is the need for
purification of RNA, making it less suitable for routine
procedures. To date, a number of laboratories have success-
fully performed PCR directly on clinical material, after a
simple pretreatment (direct PCR), for the detection of mi-
croorganisms (19, 21).
To investigate the most sensitive and simple PCR for the
detection of M. pneumoniae, a direct PCR, a PCR on
purified DNA (DNA-PCR), and a RT-PCR were compared
with PCR with either 16S rDNA or 16S rRNA as targets (20).
The optimal PCR method was compared with culture and
serology in a study of 98 clinical samples collected from the
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respiratory tracts of 79 patients with symptoms of respira-
tory tract infections.
MATERIALS AND METHODS
Mycoplasma strains and clinical samples. The following M.
pneumoniae isolates were used: P84 and P71 (Department of
Mycoplasma Research, National Institute of Public Health
and Environmental Protection, Bilthoven, The Nether-
lands). Clinical specimens were obtained from 79 patients
with symptoms of a respiratory tract infection. The ages of
the patients ranged from 1 week to 85 years. Fifty-three
subjects were inpatients of the Free University Hospital
Amsterdam, and 26 patients visited the outpatient clinic. The
following materials were collected from the respiratory tract:
sputum (n = 25), throat (n = 42), and nasopharyngeal (n = 4)
swabs; bronchial lavages (n = 24); nasopharyngeal aspirates
(n = 2); and pleural fluid (n = 1). All samples were sent to the
laboratory for routine culture of M. pneumoniae. A single
serum sample was available from each of 34 patients, and at
least two consecutive serum samples were available from 25
patients.
Culture. Both M. pneumoniae P84 and P71 were grown in
SP4 broth. After a color change, the number of CFU was
determined by culturing 100 pl of a 10-fold serial dilution on
PPLO plates, which were subsequently incubated at 37°C in
5% CO2 for 2 weeks. After collection, throat or nasopharyn-
geal swabs were placed directly into 3 ml of SP4 broth. The
swabs were twirled, expressed against the side of the tube,
and discarded. Of the aspirate, lavage, and sputum samples,
approximately 200 ,ul was put into 3 ml of SP4 broth after
arrival at the laboratory. Highly viscous material was first
made soluble by adding an equal volume of Sputolysin
(Behring Diagnostics), and the mixture was vigorously
shaken for 0.5 h on an automatic shaker (Marius, Utrecht,
The Netherlands). Two milliliters of the broth was incubated
at 37°C, and 200 ,ll was subsequently cultured on PPLO
(37°C, 5% C02) plates either after a color change or blindly
after 7 and 21 days of incubation. During the 3 weeks of
incubation, the plates were checked twice weekly under an
inverted microscope for the presence of Mycoplasma colo-
nies. Identification of the Mycoplasma isolates was per-
formed by the department of Mycoplasma Research, Na-
tional Institute of Public Health and Environmental
Protection. In addition, a small amount of a number of
patient samples were cultured on modified Herderschee
broth and agar and incubated at 37°C (95% N2 and 5% C02)
by the National Institute of Public Health and Environmen-
tal Protection. Identification was done by identifying the
colonies that appeared on the agar plates by indirect immu-
nofluorescence by using specific polyclonal rabbit antibody
for M. pneumoniae and horse anti-rabbit immunoglobulins
labelled with fluorescein isothiocyanate.
Serology. A commercially available microparticle aggluti-
nation assay (MAG assay; Serodia Myco II; Fujirebio, Inc.,
Tokyo, Japan), which has been shown to be specific and
sensitive for the diagnosis of M. pneumoniae infections (3),
and the complement fixation test were used as serological
tests. Paired serum specimens were tested by the comple-
ment fixation test and the MAG assay; single serum samples
were tested by the MAG assay only. An antibody titer of
.160 in the agglutination assay and a fourfold rise in titer in
paired serum specimens in the complement fixation test and
the MAG assay were regarded as positive results.
Pretreatment of Mycoplasma strains. To compare the sen-
sitivity of the direct PCR with those of the PCRs performed
on purified DNA (DNA-PCR) and RNA (RT-PCR), a 10-fold
dilution series of both M. pneumoniae P71 and P84 ranging
from 1.5 x 106 to 1.5 x 101 CFU/ml was made in Tris HCl
(pH 7.5). The influence of background human DNA on the
sensitivity of the different PCRs was tested after adding 105
HeLa 229 cells to each dilution. For the direct PCR, 10 ,ul of
each dilution was incubated for 1 h at 50°C after adding a
proteinase K buffer (500 plg of proteinase K per ml, 0.45%
Nonidet P-40, 0.45% Tween 20, 100 mM KCl, 20 mM Tris
HCl, 3 mM MgCl2) to an end volume of 25 RI, and the
mixture was subsequently boiled for 10 min to inactivate the
proteinase K. DNA and RNA were isolated from each
dilution by the method described by Gough (7). Briefly, 200
pl of cold 10 mM Tris HCl (pH 7.5)-0.15 M NaCl-1.5 mM
MgCl2-0.65% Nonidet P-40 was added to 200 ,lI of each
dilution on ice. After vigorous vortexing, the nuclei were
removed by centrifugation for 5 min at 800 x g and the
cytoplasmic lysate was carefully removed and placed in a
new tube containing 200 ,lI of 7M urea-15% sodium dodecyl
sulfate (SDS)-0.35 M NaCl-10 mM EDTA-10 mM Tris HCl
(pH 7.5) plus 400 ,u of phenol-chloroform-isoamylalcohol
(50/50/1); the mixture was then vortexed vigorously. The
deproteinized extract was separated from the phenol phase
by centrifugation, and the DNA and RNA was recovered by
precipitation of the aqueous phase with 1 ml of 95% ethanol
and chilling at -20°C. The DNA and RNA was resuspended
in 10 RI of distilled water. The RT reaction was performed in
a 20-pl volume containing 50 mM Tris HCl (pH 8.3) 60 mM
KCl, 3 mM MgCl2, 2.5 pmol of MPn2 (antisense primer), 20
U of Rnasin (Promega), 8 U of avian myeloblastosis virus
reverse transcriptase (Promega, Madison, Wis.), and 2 pA of
purified nucleic acids. This mixture was incubated for 1 h at
42°C. Only one-fourth of the RT reaction mixture was used
in the PCR. The DNA PCR was performed on 2 ,u of diluted
(four times) and purified nucleic acids, so that an equivalent
amount of CFU was tested by each PCR method.
Pretreatment of clinical samples. For the direct PCR, 200
pA of the SP4 broth inoculated with the clinical sample was
centrifuged for 0.5 hour at 12,000 x g. Subsequently, the
pellet was resuspended in 40 plA of Tris HCl (10 mM). Lysis
buffer containing 500 p,g of proteinase K per ml, 0.45%
Nonidet P-40, 0.45% Tween 20, 100 mM KCl, 20 mM Tris
HCI, and 3 mM MgCl2 was added to a final volume of 100 pA.
This solution was incubated overnight at 37.5°C, and the
samples were subsequently boiled for 10 min to inactivate
the proteinase K. The direct PCR was performed on 25 pl of
this product.
PCR. The nucleotide sequences of the different primers
used in the M. pneumoniae PCR (20) and the 0-globin PCR(15) are given in Table 1. The specificity of the M. pneumo-
niae PCR has been tested extensively, as described by Van
Kuppeveld et al. (20). Under the conditions used, the
primers amplified only M. pneumoniae but none of the other
Mycoplasma species or other human pathogens (20). The M.
pneumoniae PCR gave rise to a 277-bp fragment, and the
3-globin PCR gave rise to a 329-bp fragment. The oligonu-
cleotides were synthesized by using a Gene assembler plus
apparatus (Pharmacia, Uppsala, Sweden) by the methoxy
phosphoramidite method. The M. pneumoniae PCR and the
3-globin PCR were performed separately. The PCR was
performed in a total volume of 50 pA containing 50 mM KCI,
10 mM Tris HCl (pH 8.3), 1.5 mM MgCl2, 200 ,uM (each)
deoxynucleoside triphosphates, 25 pmol of each primer, 1 U
of Taq DNA polymerase, and the sample. Samples were
amplified for 40 cycles by using a PCR processor (Bio-med
60; Biomed, Theres, Germany), starting with a 4-min dena-
J. CLIN. MICROBIOL.
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TABLE 1. Sequences of primers and probe
Target primer or probe Nucleotide sequence product (bp)
16S rDNAa
M. pneumoniae 1 (sense) 5'-AAGGACCTGCAAGGGTTCGT-3' 277
M. pneumoniae 2 (antisense) 5'-CrCTAGCCATTACCTGCTAA-3'
Probe GPO-1 5'-ACT CCTACGGGAGGCAGCAGTA-3'
P-Globin geneb
PCO3 (sense) 5'-ACAGAACTGTGTTCACTAGC-3' 326
PCO6 (antisense) 5'-CAT CAGGAGTGGACAGATCC-3'
a See reference 20.
b PCO3 (15) and PCO6 (this study) were described previously, as indicated.
turation step at 95°C. In the optimized PCR, each cycle
consisted of the following steps: denaturation at 95°C for 1
min, annealing at 60°C for 1 min, and elongation at 72°C for
1.5 min. After 40 cycles, a temperature delay step of 4 min at
72°C was done to complete the elongation.
Southern blot analysis of PCR products. Ten microliters of
the PCR product was analyzed on a 1.5% agarose gel. DNA
was transferred from the agarose gel to a nylon membrane
(Gene-Screen Plus; DuPont) by diffusion blotting in 0.4 M
NaOH-0.6 M NaCl overnight. The membrane was neutral-
ized with 2x SSC (lx SSC is 0.15 M sodium chloride plus
0.015 M sodium citrate) and dried. Membranes were prein-
cubated at 55°C in a hybridization solution (0.5 M sodium
phosphate [pH 7.2], 7% SDS) for 2 h. Hybridization was
performed overnight at 55°C in the hybridization solution
containing 5'-32P-end-labelled oligonucleotide probe (6 x 104
cpm/ml) (Table 1) by standard procedures (16). Subsequent
washings were carried out at 55°C in 3 x SSC with 0.5%
SDS. Autoradiography was performed overnight at -70°C
with Kodak Royal X-Omat film and intensifying screens.
RESULTS
Comparison of direct PCR versus RT-PCR. In order to
compare the sensitivities of the different PCRs, each PCR
was performed on a serial dilution of M. pneumoniae. The
PCR was performed directly on cells by using a proteinase K
treatment (direct PCR), after purification of nucleic acids
(DNA-PCR), or after reverse transcription of rRNA (RT-
PCR). The 277-bp fragment obtained from the M. pneumo-
niae PCR was produced with both strains P71 and P84, as
detected on agarose gels and after hybridization with the
probe. The absolute sensitivity of the direct PCR was 1.5
CFU on agarose gels. A 10-fold decrease in sensitivity was
observed by the DNA-PCR. The RT-PCR restored the
initially obtained sensitivity to 1.5 CFU (Table 2). Additional
hybridization did not lead to a higher sensitivity (Fig. 1). The
TABLE 2. Comparison of the sensitivities of direct PCR, DNA-
PCR, and RT-PCR
Sensitivity (CFU)a
PCR Sample No extraneous ios HeLa cells
DNA
Direct PCR Lysed cells 1.5 1.5
DNA-PCR Purified DNA or RNA 15 15
RT-PCR Purified DNA or RNA 1.5 1.5
a Sensitivities determined by hybridization and gel analysis were identical.
addition of 105 HeLa 229 cells to each dilution did not
influence the sensitivity. Therefore, the sensitivity was 250
genomes for both the direct PCR and the RT-PCR (1 CFU
160 genomes copies, according to Harris et al. [9]).
Evaluation of the PCR on clinical samples versus culture
and serology. A 3-globin PCR was performed to test whether
the clinical samples were suitable for amplification. The
,3-globin PCR amplifying a 326-bp fragment was negative in
five samples (5.1%) (all throat swabs). A DNA or RNA
extraction was performed on these samples, and the samples
were retested by the 3-globin PCR and the RT-PCR for M.
pneumoniae. Finally, two samples (2%) remained in which
amplification was not possible. Fourteen (14.3%) of the 98
samples tested were found to be positive by the direct M.
pneumoniae PCR. M. pneumoniae DNA was detected in
seven sputum samples, one nasopharyngeal swab, and six
throat swabs. These samples were collected from 10 (12.7%)
of the 79 patients tested. Serological data were obtained
from 59 (74.7%) patients. Table 3 summarizes the results of
the comparison of serological and PCR results. Correspond-
ing negative results were obtained for 46 (77.9%) of the
patients, and corresponding positive results were obtained
for 6 (10.2%) of the patients. Discrepant results were ob-
tained for samples from 7 of the 59 patients, only 4 of which
were serologically positive and 3 only of which were PCR
positive. Of the six patients whose samples were positive by
both PCR and serology, samples from two patients were also
found to be positive by culture. Serum from one patient
whose sample was positive by PCR was not available, and
cultures of the sample from the patient remained negative.
More detailed results for the patients whose samples were
positive by any of the tests are summarized in Table 4 and
are described more extensively in the Discussion section.
DISCUSSION
Nucleic acid purification, which is often used as pretreat-
ment for PCR, is laborious and not practical for routine
procedures. A PCR performed directly on clinical samples
after a simple pretreatment is preferred. Therefore, the
sensitivity of the direct PCR was compared with those of
DNA-PCR and RT-PCR (20) on a serial dilution of M.
pneumoniae with 16S rDNA as the target. The DNA-PCR
and the RT-PCR were performed on purified nucleic acids.
In contrast to other studies (1, 11, 21), no simulated clinical
samples were used, since these may contain inhibitory
substances. This may have a different influence on each
method, making a fair comparison between the direct PCR
and the DNA-PCR and RT-PCR in a model system impos-
sible. The sensitivity of the direct PCR was identical to that
VOL. 32, 1994
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TABLE 3. Results of M. pneumoniae PCR compared with that of
serology by the MAG assay in patients with
respiratory complaints
PCR result Serology result (no. [%] of samples)
+ - Total
+ 6 (10.2) 3 (5.1) 9 (15.3)
- 4 (6.8) 46 (77.9) 50 (84.7)





FIG. 1. Sensitivity of the direct PCR (A and D), DNA-PCR (B
and E), and RT-PCR (C and F) as tested on a dilution line of M.
pneumoniae with i0W HeLa 229 cells added to each dilution. Ten
microliters of the PCR product was analyzed on a 1.5% agarose gel
stained with ethidium bromide (A, B, and C), and additional
Southern blot analysis (D, E, and F) was performed with 5'
[32P]ATP-labeled oligonucleotide GPO-i. Lanes: 1, 1.5 x 10' CFU;
2, 1.5 x 103 CFU; 3, 1.5 x 102CFU; 4, 1.5 X 102CFU; 5, 1.5 x 101
CFU; 6, 1.5 CFU; 7, 1.5 x 10-1 CFU; 8, 1.5 x 10-2 CFLl; 9, 1.5 x
i0-' CFU; 10, PCR mixture; 11, negative controle; M, molecular
length marker (Hinfl-digested plasmid pBR322; in base pairs).
of the RT-PCR and was not influenced by an excess of
background human DNA. A sensitivity greater than 1.5 CFU
(-250 genomes) achieved by the direct PCR is probably not
possible, since mycoplasmas tend to grow iif small colonies,
making suspensions of single cells impossible (9). Most
likely for similar reasons, no improvement in sensitivity after
hybridization was found, since this sensitivity was already
reached at the gel level. A loss of DNA occurs during the
purification step, as was shown by a 10-fold decrease in the
sensitivity of the DNA-PCR compared with that of the direct
PCR. This is in agreement with a study by Hammar et al. (8),
who showed a decrease in sensitivity after each subsequent
step in a purification procedure. Therefore, a purification
method with a minimum of extraction and centrifugation
steps, like the method of Gough (7), which has proved to be
fast and reliable in our laboratory, is preferred. In conclu-
sion, the results determined on an M. pneumoniae dilution
series favor the direct PCR as the method of detecting M.
pneumoniae in clinical samples because of its high sensitiv-
ity and relative simplicity.
To ensure that clinical samples were suitable for amplifi-
cation, all were first tested by performing a PCR by ampli-
fying a 326-bp fragment of the 0-globin gene. It is important
that the 3-globin PCR amplifies a fragment comparable in
length to the fragment amplified in the specific PCR, since
smaller fragments have been found to be more efficiently
amplified and less sensitive to the degradation of DNA
(unpublished data). Negative ,3-globin results were found in
only 5.1% (n = 5) of the samples by direct PCR and in 2% (n
= 2) of the samples after purification of nucleic acids; this is
in contrast to the 25% failure of amplification of ,3-globin
found by Skakni et al. (18). These findings might be ex-
plained by several differences between the studies, such as
the use of different clinical samples, a ,-globin PCR with
other primers, and a different pretreatment. All 0-globin-
negative samples in the direct PCR were throat swabs. A
negative PCR result could be the result of the small amount
of DNA available in throat swab samples or inhibition.
Amplification was successful in three of the five throat swab
samples after purification of nucleic acids, indicating the
removal of inhibitory factors.
The direct PCR for the detection of M. pneumoniae was
evaluated on clinical samples by comparing the results
obtained by the M. pneumoniae PCR with those obtained by
culture and serology. The MAG assay and direct M. pneu-
moniae PCR yielded concordant results for samples from
88.1% of the patients (Table 3). To exclude false-negative
results obtained by the direct M. pneumoniae PCR, the
RT-PCR was performed on a substantial part of samples
negative by the direct M. pneumoniae PCR (data not
shown). No additional positive samples were found in this
group, which included a sample from a serologically positive
patient. Although a good correlation was found between
serology and PCR results, samples from seven patients gave
discrepant results, as shown in Table 4. A positive serolog-
ical test with a negative PCR result was found for samples
from four patients. M. pneumoniae was probably eradicated
from two patients (patients 4 and 12), since samples for the
J. CLIN. MICROBIOL.
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TABLE 4. Results for patients with respiratory complaints and whose samples were positive for M. pneumoniae by any of the
diagnostic testsa
Titer by:
Patient Ageb Clinical status Sample PCR Culture CFT Agglutination
no. result result
Acute phase Convalescent Acute phase ConvalescentAcuepase phae Autephase phase
1 2 Myeloid leukemia TH + (4 m) - ND 32 (3 m) ND 160 (4 m)
Prolonged rhinitis TH + (6 m) -
and Otitis media
2 22 Pneumonia SP - (10 d) - 128 (20 d) ND 160 (20 d) ND
3 22 Hyper IgE TH + (11 d) - 512 (11 d) 512 (11 d) >320 (11 d) >320 (25 d)
syndrome
Pneumonia SP + (11 d) -
SP + (21 d) -
4 31 Sarcoidosis BR - (2 m) - 64 (10 d) 32 (1 m) 40 (10 d) >320 (1 m)
Upper respiratory
infection
4 29 Pneumonia TH + (2 d) - 64 (1 d) 64 (1 d) <40 (1 d) <40 (11 d)
6 9 Asthma SP + (8 d) - 128 (5 d) ND >320 (5 d) ND
Pneumonia NP + (18 d) +
7 7 Upper respiratory TH + (19 d) - 4,112 (17 d) ND >320 (1 d) ND
infection
8 4 Pneumonia TH - (13 d) - 2,056 (16 d) ND >320 (16 d) ND
9 6 Pneumonia SP + (5 d) - 4,112 (10 d) ND >640 (10 d) ND
10 8 Pneumonia TH + (9 d) + 2,056 (9 d) ND >320 (9 d) ND
11 25 Pneumonia SP + (4 d) - ND ND ND ND
12 5 Pneumonia TH - (3 m) - 1,024 (15 d) 1,024 (3 m) >640 (15 d) >320 (3 m)
512 (4 m) >320 (4 m)
13 14C IRDS NPA - (8 d) - <4 (20 d) ND <40 (20 d) ND
14 21 Leukemia SP + (1 d) - 64 (5 d) 128 (12 d) <40 (5 d) <40 (12 d)
Streptococcal sepsis <40 (1 m)
ARDS
a Abbreviations: CFT, complement fixation test; IRDS, infant respiratory stress syndrome; ARDS, adult respiratory distress syndrome; TH, throat swab; SP,
sputum; NP, nasopharyngeal swab; BR, bronchial lavage; NPA, nasopharyngeal aspiration; ND, not done; d and m, time in days and months, respectively, after
the initial symptoms that the sample was taken.
bUnits are years unless indicated otherwise.
c Age is in days.
PCR were taken after prolonged treatment with either eryth-
romycin or tetracycline and the disappearance of symptoms.
A sample error because of the small volume (50 pl) tested in
the PCR might explain the remaining two negative PCR
results (samples from patients 2 and 8), since inhibition was
excluded by a positive 3-globin PCR. A negative serological
test with a positive PCR result was obtained for samples
from three patients. Serological samples were probably
taken too early in the disease from one patient (patient 5).
The two other patients (patients 13 and 14) might represent
(transient) carriers, since the PCR result did not correlate
with the clinical and other laboratory findings. Kai et al. (12)
tested a selection of culture positive-samples and samples
from healthy volunteers. M. pneumoniae DNA from 22 of 30
culture-positive throat samples was amplified, although
these results are difficult to interpret since identification was
done by the observance of a color change in the diphasic
medium, which is not a proper identification technique for
M. pneumoniae. Skakni et al. (18) found, in contrast to what
we found in our study, a large number of M. pneumoniae
PCR-positive samples from serologically negative patients.
However, this was explained by the lack of antibody re-
sponses in samples taken too early in the disease and in
samples derived from immunocompromised patients and
patients less then 12 months old. Williamson et al. (21)
compared the results of PCR with those of an antigen
capture assay and serology, in which current, recent, and
past infections were defined by serological criteria. Their
results indicated that a laboratory diagnosis cannot rely on
direct tests such as the PCR or antigen capture assay alone,
but should also include serology. This conclusion cannot be
drawn from the results of our study. A point of interest in the
study by Williamson et al. (21) was the finding of more
positive samples by a 16S rDNA PCR than by a PCR with
the P1 adhesion gene. In conclusion, there was good agree-
ment between the serological results obtained by the MAG
assay and the direct OCR in our study. The direct PCR is the
method of choice, although the RT-PCR could prove useful
when purification of nucleic acids is indicated because of the
presehce of inhibitory substances. The loss of nucleic acids
is then compensated for by using the multiple copies of
cDNA sequences generated by the RT reaction.
Different studies have shown that M. pneunoniae can be
detected in healthy people (6, 18, 21). Therefore, it is
possible that detection of M. pneumoniae does not always
represent a pathological state. This is confirmed by the study
of Gnarpe et al. (6), in which they found the presence of M.
pneumoniae by culture in 4.6% of healthy volunteers; the
value rose to 13.5% during a peak period in the incidence of
M. pnewmoniae. However, the fact that these findings reflect
the very early phase (incubation phase) of a subsequent
clinical infection cannot be excluded. Skakni et al. (18) and
Williamson et al. (21) showed in their studies that PCR is
capable of detecting M. pneumoniae in serologically nega-
tive patients and in patients with a past infection. The latter
patients represented those in a convalescent-phase carrier
VOL. 32, 1994
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state, such as three patients (patients 1, 3, and 6) in the
present study in whom M. pneumoniae DNAwas detected 3
weeks to 6 months after the start of the illness. M. pneumo-
niae DNA was also detected in two patients (patients 13 and
14) who clearly had other causes for their respiratory prob-
lems. Probably because of its high sensitivity, PCR is
capable of detecting M. pneumoniae in circumstances other
than acute infections. Therefore, PCR could be an attractive
test for studying this persistence. On the other hand, it will
prove difficult to correlate a positive PCR result with clinical
symptoms if this persistence or carriage in healthy people is
much more common then was presumed.
The PCR could also prove useful in the diagnosis of
extrapulmonary M. pneumoniae infections. Narita et al. (14)
showed that M. pneumoniae DNA can be detected by PCR
in the sera and cerebrospinal fluid of patients with clinical
central nervous system infections. M. pneumoniae DNA in
cerebrospinal fluid could be detected by the direct PCR
described in the present study in a 9-year-old patient with
high serological titers who died of encephalitis (data not
shown). This patient and other serologically positive patients
with symptoms of an central nervous system infection will
be more extensively described in a future report.
In conclusion, theM. pneumoniae PCR directed at the 16S
rRNA gene from respiratory tract samples after a simple
pretreatment was found to be at least as sensitive and more
practical than an RT-PCR. The RT-PCR was useful after
nucleic acid purification, as indicated by the presence of
PCR inhibition, since the improved sensitivity compensated
for the loss of nucleic acids. Inhibition or loss of nucleic
acids was encountered in only a small percentage of samples
after a simple pretreatment protocol. Therefore, the direct
16S rRNA PCR proved to be valuable as a technique for
detecting M. pneumoniae in respiratory tract samples, al-
though future studies must be performed to evaluate the
correlation between a positive PCR result and clinical symp-
toms. These investigations will be performed on samples
from children with community-acquired respiratory infec-
tions.
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